Leaflet ZEVALIN 1.6mg / ml kit
Indicated for: lymphoma
Route of administration: injectable
Substance: ibritumomab tiuxetan (monoclonal antibody)
ATC: V10XX02 (Various | Other therapeutic radiopharmaceuticals | Various therapeutic radiopharmaceuticals)
Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.
This medicine is subject to additional monitoring.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
Ibritumomab tiuxetan is a radioactive monoclonal antibody used for the treatment of non-Hodgkin's lymphoma. It works by binding to the CD20 antigen on the surface of B-lymphocytes, destroying cancer cells through radiation and immune mechanisms.
The medication is administered intravenously, as directed by a doctor, and requires careful monitoring for adverse effects.
Side effects may include nausea, fever, fatigue, decreased blood cell counts, or allergic reactions. In rare cases, severe infections or tumor lysis syndrome may occur.
Ibritumomab tiuxetan is not recommended for patients with hypersensitivity to this medication or active severe infections.
General data about ZEVALIN 1.6mg / ml
- Substance: ibritumomab tiuxetan
- Date of latest medicines list: 01-07-2013
- Product code: W42167001
- Concentration: 1.6mg / ml
- Pharmaceutical form: kit
- Quantity: 1
- Product type: Original
- Prescription status: S - Medicines dispensed with a restricted medical prescription, reserved for use in certain specialized fields.